Bristol-Myers Squibb: Liver Diseases trials

The registry lists 25 Liver Diseases studies with Bristol-Myers Squibb as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 20Phase 2 3Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver FibrosisTerminatedNCT04048876Phase 2Results posted
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver CirrhosisCompletedNCT03486912Phase 2Results posted
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver FibrosisCompletedNCT03486899Phase 2Results posted
• Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic ImpairmentCompletedNCT00162097Phase 1Results posted
• Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic ImpairmentCompletedNCT06535399Phase 1
• Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic ImpairmentCompletedNCT06425198Phase 1
• A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic ImpairmentCompletedNCT06352528Phase 1
• A Study of Mezigdomide in Healthy Participants and Participants With Hepatic ImpairmentCompletedNCT05707390Phase 1
• A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of SitravatinibCompletedNCT04772612Phase 1
• A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver DiseaseTerminatedNCT04766476Phase 1
• A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of OzanimodCompletedNCT04639115Phase 1
• Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic ImpairmentCompletedNCT04573582Phase 1
• A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver ImpairmentCompletedNCT04225936Phase 1
• A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic ImpairmentCompletedNCT03983161Phase 1
• An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver DamageCompletedNCT03890809Phase 1
• Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy SubjectsCompletedNCT03824678Phase 1
• A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy SubjectsCompletedNCT03742882Phase 1
• An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney FunctionCompletedNCT03674476Phase 1
• An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver FunctionCompletedNCT03515980Phase 1
• A Study of Experimental Medication BMS-986036 Given to Healthy ParticipantsCompletedNCT03445208Phase 1
• A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.CompletedNCT03290443Phase 1
• A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy ParticipantsWithdrawnNCT02985632Phase 1
• Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic ImpairmentCompletedNCT01762462Phase 1
• Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver DiseaseCompletedNCT00529178Phase 4
• A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study DrugCompletedNCT00382668